MIMIC-3D is developending the next generation of 3D cell culture solutions. Our platform addresses the critical disconnect between flat cell culture and in vivo biology
MIMIC-3D is an innovative platform that combines 3D-bioprinting with cryogenics and stem cell technology to revolutionize preclinical testing. Our proprietary freeze-lock process enables unprecedented control over tissue architecture while maintaining long-term stability. This convergence of cutting-edge technologies creates a paradigm shift in how pharmaceutical companies evaluate therapeutic candidates.
Generates 3D cell culture solutions that better mimic real tissues for predictive assays. Our models capture the cellular heterogeneity, matrix composition, and microenvironmental cues that drive therapeutic response.
Fully storable, shippable, and highly reproducible, enabling true batch regulation. Extended shelf life eliminates the pressure of working with fresh cultures and enables inventory management at scale.
An 'off-the-shelf' model for on-demand use, eliminating lead times. Researchers can initiate experiments immediately, accelerating discovery timelines and enabling rapid iteration of experimental designs.
> 90% viability after thawing, maintained for over 2 weeks. Enables longitudinal studies and complex drug screens. Extended culture periods support chronic dosing studies, metabolite analysis, and adaptive resistance modeling—critical for evaluating next-generation therapeutics.
Full control over pore size facilitates media exchange and cell migration studies. Increased dimensions (up to 10cm) allow for large-scale analysis. Our tunable architecture supports both diffusion-limited and perfusion-based experimental designs, accommodating diverse assay requirements.
Precise location control for Mesenchymal stem cells, IPS cells, Endothelial, Neural, and various Cancer types. Multi-lineage co-culture systems recreate the cellular cross-talk that drives tumor progression, immune evasion, and therapeutic resistance in vivo.